{
    "organizations": [],
    "uuid": "56fb93997d40bdf2f4a4bae515ea313b99eb7d31",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-diamyd-medical-gaba-diamydtrial-in/brief-diamyd-medical-gaba-diamydtrial-in-the-us-fully-recruited-idUSFWN1QC0BW",
    "ord_in_thread": 0,
    "title": "BRIEF-Diamyd Medical: GABA/Diamyd Trial In The US Fully Recruited",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 22 (Reuters) - DIAMYD MEDICAL AB:\n* THE GABA/DIAMYD® TRIAL IN THE US FULLY RECRUITED THIS SUMMER\n* ‍NO SERIOUS SIDE EFFECTS HAVE BEEN REPORTED AND TREATMENT APPEARS TO BE SAFE.​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-22T15:46:00.000+02:00",
    "crawled": "2018-02-23T15:34:24.003+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "diamyd",
        "medical",
        "ab",
        "trial",
        "u",
        "fully",
        "recruited",
        "summer",
        "serious",
        "side",
        "effect",
        "reported",
        "treatment",
        "appears",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}